eFFECTOR Therapeutics, Inc. Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing a new class of oncology drugs known as selective translation regulators. Its products are designed to target a single protein that modulates the expression of multiple related proteins involved in immune evasion, cellular stress and inflammatory responses, and cell proliferation, aiming to influence multiple cancer biology pathways. The company collaborates with research institutions on investigator-sponsored trials and seeks to advance combination strategies in various cancer contexts. Headquartered in Solana Beach, California, the organization operates in a research-driven segment of the biotechnology industry and has pursued partnerships and clinical investigations to evaluate its therapeutic approach. Recent activity includes collaborations with the Dana-Farber Cancer Institute on a Phase 2 trial evaluating zotatifin in ER+ endometrial cancer and low-grade serous ovarian cancer, reflecting its ongoing emphasis on clinical development through external collaborations.